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1Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality worldwide1.We performed a genetic association in 15,256 cases and 47,936 controls, with replication of selecttop results (P < 5x10-6) in 9,498 cases and 9,748 controls. In the combined meta-analysis, weidentified 22 loci at genome-wide significance, of which 15 have been associated with lung functionin general population samples, and 4 (EEFSEC, DSP, MTCL1, and SFTPD) are novel. We noted 2 locishared with pulmonary fibrosis (FAM13A and DSP) but with opposite risk alleles for COPD. None ofour loci overlapped with genome-wide associations for asthma; however, one locus has beenimplicated in the joint susceptibility to asthma and obesity. We also identified genetic correlationbetween COPD and asthma. Our findings highlight novel loci, demonstrate the importance ofspecific lung function loci to COPD, and identify potential regions of genetic overlap between COPDand other respiratory diseases.
COPD is characterized by persistent and progressive airflow limitation diagnosed by lungfunction testing1. While cigarette smoking is the major risk factor, susceptibility is also influencedby genetics2-4. We established the International COPD Genetics Consortium (ICGC) to coordinateefforts to find susceptibility loci5. We defined cases based on pre-bronchodilator evidence ofmoderate-to-severe airflow limitation by modified GOLD criteria6; controls had normal spirometry,and all analyses were adjusted for age and cigarette smoking (pack-years and smoking status). Weperformed a two-stage genome-wide association study (Figure 1). In Stage 1, we combined 26cohorts (Supplemental Table S1) containing 63,192 individuals (15,256 COPD cases and 47,936controls). We selected 79 loci with P < 5x10-6 and in analysis Stage 2, we tested them in the UKBiLEVE dataset (9,498 COPD cases and 9,748 controls) from the UK Biobank and performed anoverall meta-analysis (Supplemental Table S3).We identified 13 genome-wide significant (P < 5x10-8) associations in Stage 1. Following theStage 2 analysis, an additional 9 loci achieved genome-wide significance in the overall meta-
2analysis (Table 1 and Figure 2). Of the 22 genome-wide significant loci described in our study, 9have been previously described as genome- (or exome-) wide significant in studies of COPD4,7-10:
HHIP, CHRNA5/15q25, HTR4, FAM13A, RIN3, TGFB2, GSTCD/NPNT, CYP2A6/19q13, and16p11.2/IL27. An additional 8 loci: ADGRG6/GPR126, THSD4, ADAM19, TET2, CFDP1, AGER, ARMC2,and RARB have been previously described and replicated (Supplemental Table S6) in generalpopulation GWASs of two measures of lung function (FEV1 and FEV1/FVC) that are used inconjunction to diagnose COPD11-17. One locus near PID1 was previously associated with FEV1/FVC,but had not replicated in those studies13,17. Four loci are newly being described as genome-widesignificant in association with either COPD or lung function: EEFSEC, DSP, MTCL1, and SFTPD(Figure 3).To explore the potential function and causal genes for our novel loci, in addition to usingpublicly available datasets and prioritization tools (Supplemental Table S7), we also examined alarger set of lung expression quantitative trait loci (eQTL) in 1038 subjects, including subjects withCOPD18 (Supplemental Table S8). As eQTL are pervasive, we also attempted to determine whetherour association signal co-localized19 with an eQTL signal in lung tissue (Supplemental Table S9).We found strong evidence of co-localization (posterior probability > 0.8) for DSP, a major protein ofdesmosomes required for epidermal integrity 20, and MTCL1, important in epithelial-cell-specificmicrotubule stabilization21,22, and expressed in respiratory epithelial cells23. Variants in strong LDwith our top MTCL1 variant rs647097 appear to have enhancer histone marks in fetal lungfibroblasts24,25. In contrast, we found no evidence of a strong eQTL signal or co-localization at ourother two novel loci. At 3q21, EEFSEC is a potential candidate, as it is a paralog of TUFM, a topblood and lung eQTL gene for the 16p11.2/IL27 COPD susceptibility locus10, recently part of a novelCOPD-related pathway involving NLRX126-28. At 10q22, pulmonary surfactant-associated protein D(SFTPD) is the most likely candidate, as it is highly expressed in pneumocytes23, and sftpd (-/-) micedevelop pulmonary emphysema29. SFTPD has been explored as a COPD biomarker30, and while
3rs721917 is not an eQTL, polymorphisms in SFTPD, including rs721917, may lead to decreasedsurfactant protein D levels31; though the association of SFTPD polymorphisms with COPDsusceptibility have been inconsistent. Our analysis also led to some additional insights into otherpreviously described loci. We found evidence of COPD association and eQTL statistical co-localization in lung tissue (posterior probability > 0.8) for THSD4, HHIP, AGER, CHRNA3, and RARB(Supplemental Table S9). Additional data on eQTLs (Supplemental Table S8), cohort-specificassociations at each locus (Supplemental Figures S1a-v), fine mapping (Supplemental Results andTable S20), and other supportive analysis for previously described and novel loci can be found inthe Supplemental Materials.We noted that our top variant at DSP (rs2076295) is also associated (P = 1.1x10-19) withpulmonary fibrosis32. Recently, a re-sequencing study33 at this locus identified a second fibrosis-associated variant (rs2744371). We performed additional analysis to investigate genetic overlap inthis region using gwas-pw34 (see Supplement). We found a posterior probability of > 0.99 foroverlap at the FAM13A locus (top fibrosis SNP, rs2609255; Pfibrosis = 2.20x10−11, PCOPD = 1.9x10-7) anda posterior probability of 0.84 for overlap near MAPT/KANSL1 (top Pfibrosis = 8.87×10–14, PCOPD =4.5x10-3); while the latter locus did not reach genome-wide significance in our study, we note itsindependent discovery in a genome-wide association in extremes of lung function16. Notably, for allfour of these variants, the fibrosis risk allele is protective for development of COPD. Emphysema, akey component of COPD, and pulmonary fibrosis are both smoking-related lung diseases that haveboth shared and distinct pathophysiology35-37, though genetic loci with opposing effects have notbeen previously described. Additional investigation of these loci as a well as a more comprehensiveassessment of genetic overlap of COPD and pulmonary fibrosis may lead to insight into bothdisorders.Because our analysis relied on a spirometric definition of COPD alone, we did notspecifically exclude other causes of airway obstruction such as asthma, which can overlap with
4COPD in adults38. To define COPD, we used pre-bronchodilator spirometry, which was availableacross all cohorts, and we included at least moderately affected cases (FEV1 < 80% predicted). Weexamined the top set of genome-wide significant results in a subset of our largest cohorts with bothpre- and post-bronchodilator data and densely imputed genotypes; overall, the effect sizes (meandifference = 0.001) and P values (mean log10 P value difference = 0.18) were similar (SupplementalTable S10 and Supplemental Figures S4 and S5). In addition, a recent GWAS of FEV1, FVC, andFEV1/FVC did not find substantial differences including and excluding subjects with asthma16. In the79 variants tested in Stage 2, we found no significant difference in the OR for COPD associationwhen including and excluding individuals with asthma (Supplemental Figure S6). We examinedCOPD associations of genome-wide significant asthma (and asthma-associated traits) loci from theNHGRI-EBI GWAS Catalog39 (Supplemental Table S11). We also compared our COPD associationresults to the GABRIEL asthma study40 (Supplemental Tables S12). None of the genome-widesignificant loci from asthma and COPD overlapped. Further, no asthma or COPD loci showedBonferroni-adjusted (for number of look-ups) significant association with the other disease, thoughseveral loci showed nominal (P<0.05) significance (Supplemental Tables S11 and S12). The 16p11.2(CCDC101) locus has been described in the joint susceptibility to asthma and obesity41. COPDsusceptibility is strongly related to cigarette smoking. Two of our loci (15q25 and 19q13) havebeen previously associated with smoking behavior42,43, though we found no additional evidence ofoverlap in genome-wide significant variants described in the NHGRI-EBI GWAS Catalog39 andTobacco and Genetics Consortium GWAS43 (Supplemental Tables S13-S15). In contrast to minimaloverlap in genome-wide significant results with asthma and smoking, we discovered a significantoverall genetic correlation of COPD with asthma (rgenetic = 0.38, P = 6.2x10-5) using LD scoreregression in our white subjects44,45. We also assessed genetic correlation with population-basedlung function, pulmonary fibrosis, smoking behavior, and two common COPD comorbidities,coronary artery disease and osteoporosis. We identified significant correlation of COPD with lung
5function and two aspects of smoking behavior, but not with common comorbidities or withpulmonary fibrosis (Figure 4). The lack of significant correlation of COPD with pulmonary fibrosismay indicate our overlapping loci for COPD and pulmonary fibrosis are not representative of abroader disease correlation; alternatively, it could reflect limited sample size or a mix of positiveand negative genetic correlations across the genome for the diseases. In potential support of thislatter hypothesis, and in contrast to the loci we describe in this study, are recent descriptions ofrare variants in telomere genes predisposing to both emphysema, a key feature of COPD, andpulmonary fibrosis37,46. Our analysis of partitioned heritability identified COPD genetic associationenrichment in fetal lung tissue (coefficient P = 3.5x10-7); other analyses also support lung tissue orlung cell types (Supplemental Materials).Our study is, to our knowledge, the largest genome-wide association study of COPD cases todate and includes over 60,000 subjects (including 15,256 COPD cases) in our Stage 1 analysis. Wechose to combine subjects of different ethnicities, hypothesizing that the benefit of shared riskfactors across ethnicities would outweigh power loss due to heterogeneity. While methods havebeen developed that can more rigorously assess the degree of overlap and provide additionalpower in this setting47, none of our non-white cohorts were sufficiently sized or powered for theseanalyses. COPD is also a highly heterogeneous disease; whether a more precise phenotypicdefinition would result in greater power is not clear. We used a staged study design and examinedoverall meta-analysis P-values to determine genome-wide significance. Thus, 9 loci (TET2, CFDP1,
TGFB2, AGER, ARMC2, PID1, MTCL1, SFTPD, and CYP2A6) from our Stage 1 analysis, which onlyreached genome-wide significance in either the Stage 2 UK BiLEVE analysis or the overall meta-analysis, should be further replicated. However, six of these 9 association signals are significant ifwe consider a Bonferroni correction (P < 6.3x10-4) for the 79 variants tested in Stage 2. Further, 8 ofthese 9 variants become more significant from the Stage 1 analysis to the overall meta-analysis,
6with the exception of RARB, which has a previously reported association with both lung function13and airflow obstruction15 (Table 1).The majority of our significant loci overlap with lung function loci, strengthening thefoundation for investigating the relationship of lung function variability in the general population torisk of developing COPD. These loci are unlikely to reflect susceptibility for asthma or for cigarettesmoking; however, our association as a whole shows evidence of shared heritability with asthma(supporting investigation into shared genetic etiologies for these diseases) and cigarette smokingbehavior (despite adjustment for smoking in our statistical model). We identified enrichment forfetal lung cells, supporting a role for early life events contributing to future risk of COPD. Finally, weidentify loci that overlap with pulmonary fibrosis, but with opposite risk alleles. Our studyhighlights the important contribution of genetic association studies to understanding COPD, notonly by identifying novel loci, but also illustrating relationships with other pulmonary traits anddiseases.
7Online Methods
Study CohortsWe invited investigators from 22 studies with genome-wide association data and COPDcase-control or general population samples with spirometry to participate in a genome-wideassociation meta-analysis. Additionally, we included four cohorts with Illumina HumanExome v1.2and custom genotyping based primarily on prior top results from a previously published COPDGWAS4, using results with P < 1x10-4 using plink ‘--clump’ on the COPDGene non-Hispanic whites toperform linkage disequilibrium pruning (r2 < 0.8), preferentially retaining both an imputed andgenotyped top SNP at each locus. An additional group of variants was a candidate panel, based onresults from a previous candidate gene analysis48, as well as variants identified in association withlung function (supplementing the existing content on the array, which included variants fromprevious genome-wide association studies), including the lead SNP and a 200kb region around thatSNP pruned for variants with P < 0.01 and r2 < 0.8, and additional top-ranked SNPs for COPDGene-specific analyses for lung function, bronchodilator responsiveness, exacerbations, and SNPs fromcandidate genes.The baseline characteristics of these 26 cohorts can be seen in Supplemental Table S1. Eachcohort obtained approval from appropriate ethical/regulatory bodies; informed consent wasobtained for all individuals. (Further cohort-specific methods can be found in the DataSupplement.) As most of these cohorts did not have post-bronchodilator spirometry, we used amodified definition of GOLD criteria based on pre-bronchodilator spirometry: forced expiratoryvolume in 1 second (FEV1) < 80% and FEV1 to forced vital capacity (FVC) ratio of < 0.7 for cases,and FEV1 > 80% and FEV1/FVC > 0.7 for controls. Logistic regression was performed in each cohort,adjusting for age, sex, pack-years of smoking, ever-smoking status, current-smoking status, andancestry-based principal components, as appropriate for each study. Summary statistics were
8assessed using EasyQC49 version 10.1. More detailed cohort information, including cohort-specificmethods, can be found in the Data Supplement.
Genome-wide association quality controlSummary statistics, including effect allele and other allele oriented to the + strand, effectallele frequency, chromosome and position (hg19), and imputation quality were uploaded to asecure site at the Brigham and Women’s Hospital / Channing Division of Network Medicine. Qualitycontrol assessments included assessing allele frequencies versus 1000 Genomes reference,standard error versus sample size, and quantile-quantile plots. Variants with an imputation qualitymetric of < 0.3 (provided a higher threshold for imputation quality was not already implemented), aminor allele count (MAC) of < 20 using the effective sample size or the number of cases andadjusted for imputation quality where applicable, were set to missing. Variants were included formeta-analysis if they were present in at least 13 studies (those with European ancestry and at least7 million markers passing all quality control filters).
Staged GWAS meta-analysisIn Stage 1 of the analysis, we used Metal50,51 version 2011-03-25 to perform a fixed-effectsmeta-analysis of genome-wide data from 22 studies and four additional COPD cohorts genotypedon an Illumina HumanExome v1.2 platform with custom content; this content included a set ofCOPD candidate genes and regions identified from prior COPD GWAS efforts4. We adjusted forinflation using genomic control correction in each study. We included study populations withsubjects of non-European ancestry in the overall analysis, and additionally examined results limitedto study populations of European ancestry. To identify variants to test for association in Stage 2 inthe UK BiLEVE study, we selected top results (P < 5x10-6) from the Stage 1 meta-analysis. Weselected one lead variant from the chromosome 15q25, FAM13, and HHIP regions, as all of thesehave been described in multiple COPD GWASs4,7,8,15. For the remainder of the regions, we performedlinkage disequilibrium pruning using the plink2 --clump procedure with an r2 of 0.5, additionally
9examining these SNPs for the number of cohorts with passing quality control at each variant andincluding SNPs in strong LD (i.e., part of the same clump) with a lower degree of missingness. Toidentify independent results, we used GCTA-COJO52,53 on the Stage 1 meta-analysis for variants withP < 5x10-6 using the default distance of 10Mb. We used the COPDGene non-Hispanic whites (as thelargest representative population) as the reference population for these analyses. An overall meta-analysis across the Stage 1 and Stage 2 (UK BiLEVE) cohorts was performed and variants with P <5x10-8 were considered genome-wide significant (Figure 1).
Lung eQTL analysisLung expression quantitative trait loci (eQTL) were calculated from 1,111 human subjectswho underwent lung surgery at three academic sites, Laval University, University of BritishColumbia (UBC), and University of Groningen, henceforth referred to as Laval, UBC, and Groningen,respectively. This lung eQTL dataset has been described previously18,54. Briefly, 66.7% to 91.2% ofthe individuals in this study were current or former smokers and 24.2% to 35.3% had moderate tosevere COPD (GOLD spirometry grade 2 to 4). Whole-genome gene expression profiling in the lungwas performed on a custom Affymetrix array (GPL10379). Microarray pre-processing and qualitycontrols were described previously18,55,56. Probe sequences were mapped to the human genome(hg19) using Bowtie57 and probes not mapping to a coding region or having a common SNP (MAF ≥ 5%) in their sequence were removed. Expression data were adjusted for age, sex, and smokingstatus using residuals obtained with the robust fitting of linear models function (rlm) in the Rstatistical package MASS. Residual values deviating from the median by more than three standarddeviations were filtered as outliers. Genotyping was carried on the Illumina Human 1M-DuoBeadChip array.Twenty-one out of the 22 SNPs (in main manuscript Table 1) were genotyped or imputed inthe three cohorts, i.e. Laval, UBC, and Groningen. One of the SNPs, rs7186831, was not well-imputed; a proxy, rs11865296 in modest linkage disequilibrium (r2 = 0.54, 1000 genomes phase 3,
10
EUR) was used instead. These variants were tested for association with adjusted expression traits(43,465 probe sets) in the lung. SNPs within 1 Mb up and downstream of the transcription probeset were considered as local-eQTL. Distant-acting eQTLs were further than 1 Mb away or on adifferent chromosome. Association tests were carried with PLINK1.958,59 in each cohort and thenmeta-analyzed using Fisher’s method. All local eQTL with nominal P value < 0.05 in the meta-analysis were considered. To provide an additional overall estimate of eQTL significance, weconsidered a Bonferroni correction threshold ([0.05/(22 SNPs x 43,465 probe sets) = P value < 5.2x 10-8]). Statistical analyses were performed in R3.2.360.
Co-localization AnalysisCo-localization of statistical signals between COPD genetic association and eQTL wereexamined using the coloc R package19. We used phenotypic summary statistics from whites withgenome-wide association data and all eQTL results and examined 500kb flanks around the top 22genome-wide significant associations found in the overall meta-analysis (Table 1).
Sensitivity AnalysisTo estimate the effect of using pre- instead of post-bronchodilator lung function on ourresults, we examined the top set of genome-wide significant results in our largest cohorts with bothpre- and post-bronchodilator data and densely imputed genotypes (COPDGene NHW and AA,ECLIPSE, NETT-NAS, and Norway / GenKOLS). Since subjects from these cohorts (except forCOPDGene) were included based on post-bronchodilator values, including all subjects with COPDbased on post-bronchodilator spirometry would lead to larger sample sizes and make comparisonof P-values more difficult. Thus, we chose a random sample of post-bronchodilator cases andcontrols that matched the number of pre-bronchodilator cases and controls. We performed logisticregression using these equal sized set of pre- and post-bronchodilator cohorts, and meta-analyzedthe results.
Asthma overlap analysis
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We assessed the overlap between our results and known asthma susceptibility loci. Wedownloaded information on genome-wide significant (P < 5x10-8) associations with asthma andasthma-related traits including asthma and hay fever, asthma (childhood onset), asthma(corticosteroid response), bronchodilator response in asthma, pulmonary function decline, andsevere asthma in the NHGRI-EBI GWAS Catalog39. Additionally, we examined top associatedvariants (which were not genome-wide significant) in the susceptibility to the asthma-COPDoverlap syndrome61. In all, we assessed the association statistics of 49 unique asthma-associatedtrait loci across 26 genomic regions in our Stage 1 meta-analysis results. We also examined theasthma association statistics of our top COPD loci from overall meta-analysis using publicallyavailable asthma GWAS data from the GABRIEL Consortium40. For COPD loci not present in theGABRIEL Consortium asthma GWAS data, we attempted to examine proxy SNPs in LD (r2 > 0.5,1000 genomes phase 1 CEU) with our top COPD loci.To examine the genetic correlation45 of COPD and asthma over the entire genome, weperformed LD score regression44 using summary statistics from publically available asthma GWASdata from the GABRIEL Consortium40. For all comparisons using LD score regression, we filtered toHapMap3 variants, limited to white subjects with genome-wide data, and filtered on missingnessusing default parameters in munge_sumstats.py. For the GABRIEL data, we required a variant to bepresent in at least 35 of the studies.
Smoking behavior overlap analysisWe downloaded information on genome-wide significant (P < 5x10-8) associations with thetraits “nicotine dependence” and “smoking behaviour” in the NHGRI-EBI GWAS Catalog39. Weassessed these top smoking-associated SNPs in our Stage 1 meta-analysis results. We also assessedoverlap of smoking and COPD in the publically available summary statistics from the 2010 Tobaccoand Genetics Consortium GWAS43. We evaluated our top COPD loci associations from overall meta-analysis with both cigarettes per day and ever-smoking traits. For COPD risk SNPs not directly
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analyzed in the Tobacco and Genetics Consortium GWAS, we attempted to examine proxy SNPs inLD (r2 > 0.5, 1000 genomes phase1 CEU) with our top COPD loci.To examine the genetic correlation45 of COPD and smoking behaviours (cigarettes per dayand ever-smoking status) over the entire genome, we performed LD score regression44 usingsummary statistics from our current COPD study as noted above and publically available summarystatistics from the 2010 Tobacco and Genetics Consortium GWAS43.
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Table 1. Overall study results showing 22 loci with genome-wide significant P values in overall meta-analysis following UK BiLEVE Stage2 analysis.
rsID
Closest
Gene Locus
Risk
Allele
Alt
Allele
Risk Allele
Mean Freq (Range)
Stage 1
OR (95% CI)
Stage 1
P Value
UK BiLEVE (Stage 2)
OR (95% CI)
UK BiLEVE
(Stage 2)
P Value
Overall
Meta-Analysis
P Value
rs13141641 HHIP 4q31.21 T C 0.594 (0.524-0.886) 1.231 (1.183-1.281) 1.16E-24 1.213 (1.16-1.267) 8.15E-18 9.10E-41
rs17486278 CHRNA5 15q25.1 C A 0.351 (0.244-0.442) 1.224 (1.177-1.273) 2.61E-24 1.126 (1.077-1.178) 2.35E-07 1.77E-28
rs7733088 HTR4 5q32 G A 0.602 (0.47-0.685) 1.178 (1.129-1.229) 4.40E-14 1.177 (1.127-1.229) 1.78E-13 5.33E-26
rs9399401 ADGRG6 6q24.1 T C 0.724 (0.615-0.748) 1.141 (1.095-1.189) 3.59E-10 1.174 (1.119-1.232) 6.18E-11 1.81E-19
rs1441358 THSD4 15q23 G T 0.332 (0.194-0.546) 1.132 (1.09-1.177) 2.06E-10 1.121 (1.071-1.172) 6.87E-07 8.22E-16
rs6837671 FAM13A 4q22.1 G A 0.405 (0.364-0.582) 1.157 (1.115-1.2) 1.02E-14 1.066 (1.021-1.114) 3.75E-03 7.48E-15
rs11727735 GSTCD 4q24 A G 0.936 (0.926-0.988) 1.266 (1.167-1.374) 1.55E-08 1.246 (1.144-1.357) 4.93E-07 3.84E-14
rs754388 RIN3 14q32.12 C G 0.821 (0.804-0.865) 1.196 (1.136-1.258) 7.07E-12 1.108 (1.05-1.169) 1.85E-04 4.96E-14
rs113897301 ADAM19 5q33.3 AT A 0.175 (0.052-0.187) 1.195 (1.13-1.263) 4.52E-10 1.127 (1.066-1.192) 2.79E-05 1.58E-13
rs2047409 TET2 4q24 A G 0.618 (0.222-0.649) 1.101 (1.059-1.146) 1.58E-06 1.136 (1.087-1.188) 1.95E-08 2.46E-13*
rs2955083 EEFSEC 3q21.3 A T 0.881 (0.854-0.893) 1.195 (1.123-1.272) 2.00E-08 1.167 (1.093-1.246) 4.01E-06 4.16E-13
rs7186831 CFDP1 16q23.1 A G 0.435 (0.226-0.472) 1.125 (1.07-1.183) 3.54E-06 1.116 (1.069-1.165) 6.63E-07 1.12E-11*
rs10429950 TGFB2 1q41 T C 0.731 (0.216-0.773) 1.117 (1.071-1.164) 1.83E-07 1.096 (1.044-1.15) 1.94E-04 1.66E-10*
rs2070600 AGER 6p21.32 C T 0.955 (0.85-0.987) 1.276 (1.151-1.414) 3.54E-06 1.208 (1.105-1.319) 2.96E-05 5.94E-10*
rs17707300 CCDC101 16p11.2 C T 0.373 (0.109-0.433) 1.122 (1.079-1.167) 6.24E-09 1.063 (1.018-1.111) 6.10E-03 6.75E-10
rs2806356 ARMC2 6q21 C T 0.184 (0.052-0.242) 1.125 (1.071-1.181) 2.84E-06 1.116 (1.057-1.178) 6.88E-05 8.34E-10*
rs16825267 PID1 2q36.3 C G 0.929 (0.874-0.942) 1.242 (1.149-1.342) 5.22E-08 1.131 (1.045-1.224) 2.27E-03 1.68E-09*
rs2076295 DSP 6p24.3 T G 0.554 (0.442-0.581) 1.107 (1.067-1.149) 4.95E-08 1.061 (1.016-1.107) 7.45E-03 3.97E-09
rs647097 MTCL1 18p11.22 C T 0.269 (0.259-0.399) 1.106 (1.06-1.154) 3.03E-06 1.089 (1.038-1.142) 4.66E-04 6.14E-09*
rs1529672 RARB 3p24.2 C A 0.831 (0.675-0.862) 1.162 (1.106-1.221) 2.37E-09 1.048 (0.991-1.109) 9.95E-02 2.47E-08
rs721917 SFTPD 10q22.3 G A 0.422 (0.392-0.631) 1.092 (1.053-1.132) 2.11E-06 1.068 (1.023-1.115) 2.60E-03 2.49E-08*
rs12459249 CYP2A6 19q13.2 C T 0.662 (0.617-0.702) 1.126 (1.071-1.183) 2.89E-06 1.077 (1.029-1.127) 1.35E-03 3.42E-08*OR = odds ratio, CI = confidence interval. *Genome-wide significant in overall meta-analysis only
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Figure 1. Study design showing cohorts used in each stage of the analysis.
ARIC = Atherosclerosis Risk in Communities, B58 = British 1958 Birth Cohort, CHS = Cardiovascular Health Study, COPACETIC= COPD Pathology: Addressing Critical gaps, Early Treatment & Diagnosis and Innovative Concepts, ECLIPSE = Evaluation ofCOPD Longitudinally to Identify Predictive Surrogate End-points, eQTL = Lung Expression Quantitative Trait Loci Study, FHS =Framingham Heart Study, KARE = Korean Association Resource project, MESA = Multi-Ethnic Study of Atherosclerosis, NETT-NAS = National Emphysema Treatment Trial / Normative Aging Study, RS = Rotterdam Study, SPIROMICS = Subpopulationsand intermediate outcome measures in COPD study , EOCOPD = Boston Early-Onset COPD Study, ICGN = International COPDGenetics Network, TCGS = Transcontinental COPD Genetics Study, UK BiLEVE = UK Biobank Lung Exome Variant Evaluation;NHW = Non-Hispanic white, AA = African American, EA = European American.* Studies without genome-wide arraygenotyping (custom genotyping)
Stage 1:
26 studies represented. European
ancestry studies are shaded.
Stage 2:
Top results from Stage 1 analysis
tested in UK BiLEVE study.
Study COPD Cases Controls
UK BiLEVE Never Smokers 3737 4871
UK BiLEVE Heavy Smokers 5761 4877
TOTAL 9498 9748
Study COPD Cases Controls
ARIC 1060 6164
B58 205 3665
CHS EA 736 1586
COPACETIC 397 1906
COPDGene NHW 3068 2110
ECLIPSE 1741 149
EOCOPD* 394 495
ICGN* 1852 557
EQTL 252 224
FHS 701 5110
LifeLines 466 9863
Lovelace 259 641
MESA Caucasian 167 754
NETT-NAS 376 435
Norway/GenKOLS 846 695
RS1 112 815
RS2 94 811
RS3 106 1596
SPIROMICS 571 175
TCGS-Poland * 307 311
CHS AA 138 292
COPDGene AA 910 1556
KARE 199 6741
MESA AA 94 532
MESA Hispanic 52 548
TCGS-Korea * 153 205
TOTAL 15256 47936
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Figure 2. P values for Stage 1 analysis (small open diamonds) with overlay of overall meta-analysis P values for SNPs analyzed in UKBiLEVE Stage 2 analysis (filled circles). Gene names in gray are previously described COPD or lung function (FEV1 or FEV1/FVC) loci; blackare novel loci discovered in this study. The Stage 1 cohorts with available genotyping data (Supplemental Figures S1a-v) and the UKBiLEVE cohort determined the sample size for each top variant.
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Figure 3a-d. Regional association for novel loci. LocusZoom plots showing regional association of variants at the four novel COPD loci.The point size is proportional to the sample size, where Stage 1 cohorts with available genotyping data (Supplemental Figures S1a-v) andthe UK BiLEVE cohort determined the sample size for each top variant.
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Figure 4 Genetic correlation (using LD score regression) between COPD and other traits.Shading and numbers represents strength of correlation. * indicates nominal (P < 0.05)significance, ** indicates significant after Bonferroni correction for number of pairwisecomparisons. fev1fvc and fev1 = lung function (FEV1FVC ratio and FEV1 from CHARGE/SpiroMeta13,asthma taken from the asthma GWAS by the GABRIEL Consortium40, ild = pulmonary fibrosis fromFingerlin et al.32,62, bilSmk = subset of smokers in the UK BiLEVE study16, smkCpd = cigarettes perday smoking from the Tobacco and Genetics (TAG) Consortium43, smkFormer = current versusformer smokers from TAG, smkOnset = age of smoking initiation from TAG, smkEver = ever versusnever smoking from TAG. cad = coronary artery disease from the CARDIoGRAM study63, height64and bmi (body mass index)65 from the GIANT consortium, bmdLumbar and bmdFemoral = lumbarand femoral bone mineral density, respectively, from the Genetic Factors for Osteoporosis (GeFOS)Consortium66.
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